1-20 of 306
panobinostat
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, MS, Nicola Long, Anupriya Agarwal, PhD, Cristina E. Tognon, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner
Journal: Blood
Blood (2019) 134 (Supplement_1): 878.
https://doi.org/10.1182/blood-2019-126020
Published: 2019
Journal Articles

High Throughput Drug Synergy Testing in a Clinical Trial of Panobinostat, Carfilzomib, Dexamethasone to Define Response Biomarkers for Relapsed/Refractory Multiple Myeloma

Pamela S. Becker, MD PhD, Kim Quach, Ted A Gooley, PhD, Edward N. Libby, III, MD, Andrew J. Cowan, MD, David G. Coffey, MD, Bret Gary Degraaff, BS, Cody Hammer, Jin Dai, PhD, Sylvia Chien, Josh Epworth, ARNP, Gabrielle A Zecha, PA-C, Heather Smith, PA-C, Timothy S Martins, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1902.
https://doi.org/10.1182/blood-2019-130990
Published: 2019
Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Edward A. Stadtmauer, MD FACP, Adam D. Cohen, MD, Kristy Weber, MD, Simon F Lacey, PhD, Vanessa E. Gonzalez, J. Joseph Melenhorst, PhD, Joseph A Fraietta, PhD, Gabriela Plesa, MD, Joanne Shea, Tina Matlawski, RN, Amanda Cervini, RN, Patricia Mangan, CRNP, Avery Gaymon, Stephanie Desjardins, Eric Lancaster, MD, January Salas-Mckee, Megan M. Suhoski, PhD, Andrew Fesnak, MD, Matthew O'Rourke, Anne Lamontagne, Don L. Siegel, MD PhD, Regina M Young, PhD, Anne Chew, PhD, Christopher L Nobles, PhD, Frederic D. Bushman, PhD, Howard Y. Chang, MD PhD, Ansuman T. Satpathy, MD PhD, Yangbing Zhao, PhD MD, Wei-Ting Hwang, PhD, Elizabeth O. Hexner, MDMS, Carl H June, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 49.
https://doi.org/10.1182/blood-2019-122374
Published: 2019
Journal Articles

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Caleb K Stein, PhD, Nathalie Meurice, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Gregory J Ahmann, BS, Shulan Tian, MS, PhD, P. Leif Bergsagel, MD, Esteban Braggio, PhD, A. Keith Stewart, MB, ChB
Journal: Blood
Blood (2019) 134 (Supplement_1): 574.
https://doi.org/10.1182/blood-2019-130977
Published: 2019
Journal Articles

Multiple Myeloma :Trends in Consulting Fees and Drug Utilization

Daniel Chakos, MD, Azam Farooqui, MD, Kimberly McCormick, Abhishek R Chilkulwar
Journal: Blood
Blood (2019) 134 (Supplement_1): 5823.
https://doi.org/10.1182/blood-2019-132036
Published: 2019
Journal Articles

Subsequent Treatments, Responses and Survival in the Real World for Patients with Relapsed Multiple Myeloma Following Treatment with Lenalidomide

Jessica B Taube, MBBChir, Catherine SY Lecat, MBBS, Simon Cheesman, BPharm, Gabriel Wallis, Charalampia Kyriakou, Lydia Lee, Shameem Mahmood, Xenofon Papanikolaou, Christopher Parrish, MB BChir MA MRCP FRCPath PhD, Neil K Rabin, Sajitha Sachchithananthan, Jonathan Sive, MD, Ashutosh D. Wechalekar, Kwee Yong, Gordon Cook, Rakesh Popat
Journal: Blood
Blood (2019) 134 (Supplement_1): 4340.
https://doi.org/10.1182/blood-2019-128266
Published: 2019
Journal Articles

Differentiation Therapy with Novel Epigenetic Inhibitors in Acute Myeloid Leukemia

Edurne San Jose, Naroa Gimenez-Camino, Obdulia Rabal, Estibaliz Miranda, Leire Garate, Fernando Garcia, Ana Alfonso Pierola, MD PhD, Sara Villar, Jose J. Rifon Roca, MD, Antonio Pineda-Lucena, Bruno Paiva, PhD, Javier Muñoz, Jesús San-Miguel, Julen Oyarzabal, PhD, Xabier Agirre, PhD, Felipe Prósper, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3762.
https://doi.org/10.1182/blood-2019-125578
Published: 2019
Journal Articles

Incidence and Survival of Multiple Myeloma; A Population-Based Study on 10 961 Patients Diagnosed 1982-2017

Øystein Langseth, MD, Tor Åge Myklebust, M.sc, PhD, Tom Børge Johannesen, MD PhD, Øyvind Hjertner, MD PhD, Anders Waage, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4380.
https://doi.org/10.1182/blood-2019-129816
Published: 2019
Journal Articles

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

Ricardo De Matos Simoes, PhD, Ryosuke Shirasaki, MD PhD, Sondra L. Downey-Kopyscinski, PhD, Geoffrey Matthews, PhD, Hu Yiguo, PhD, Michal Sheffer, PhD, Eugen Dhimolea, PhD, Olga Dashevsky, PhD, Sara Gandolfi, MD, Joshua Dempster, PhD, Robin M. Meyers, PhD, Jordan Bryan, James M. McFarland, Johanna Brueggenthies, Huihui Tang, PhD, Megan Bariteau, BSc, Minasri Borah, Quinlan L Sievers, PhD, Benjamin Ebert, MD, Brian Glassner, PhD, Christopher J. Ott, PhD, Nicholas P Kwiatkowski, PhD, John G Doench, PhD, Daniel Auclair, Joan Levy, PhD, Lawrence H. Boise, PhD, Jonathan J Keats, PhD, Jonathan D. Licht, MD, Richard Groen, Nathanael Gray, Aedin Culhane, PhD, William C. Hahn, MD PhD, Francisca Vazquez, PhD, Aviad Tsherniak, PhD, Constantine S. Mitsiades, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4407.
https://doi.org/10.1182/blood-2019-130901
Published: 2019
Journal Articles

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Li Chen, PhD, Amit Kumar Mitra, PhD MSc, BSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 5543.
https://doi.org/10.1182/blood-2019-131923
Published: 2019
Journal Articles

Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma

Hong-Hui Huang, PhD MD, Jian Hou, PhD MD, Yang-Ming Zhang, PhD, Yu-Bo Zhou, PhD, Li Jia, PhD, Fa-Jun Nan, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5591.
https://doi.org/10.1182/blood-2019-129683
Published: 2019
Journal Articles

Patient-Derived Acute Myeloid Leukemia (AML) Ex Vivo platform for Evaluation of Novel Molecular Targeted Therapeutic Agents

Bhavna Verma, Nicolett Biel, Bruce Ruggeri, Amy Wesa
Journal: Blood
Blood (2019) 134 (Supplement_1): 5146.
https://doi.org/10.1182/blood-2019-126127
Published: 2019
Journal Articles

Panobinostat Potentiates Melphalan-Induced Apoptosis of Myeloma Cells and Minimizes Untoward Side Effects in Multiple Myeloma

Maria Gkotzamanidou, MD PhD, Vassilis L. Souliotis, PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2528.
https://doi.org/10.1182/blood-2019-123338
Published: 2019
Journal Articles

Generation, Characterization and Pre-Clinical Drug Evaluation of Patient-Derived Xenograft Models of Pediatric Down Syndrome AML

Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Erin Lynn Crowgey, PhD, Todd E Druley, MD PhD, Anilkumar Gopalakrishnapillai, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2683.
https://doi.org/10.1182/blood-2019-131050
Published: 2019
Journal Articles

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

Anthony Quagliano, BS, Anilkumar Gopalakrishnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 2628.
https://doi.org/10.1182/blood-2019-129198
Published: 2019
Journal Articles

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Taiga Nishihori, MD, Rachid Baz, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Frederick L. Locke, MD, Jongphil Kim, PhD, Jinming Song, MD PhD, Michael Dumala, Melissa Alsina, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3189.
https://doi.org/10.1182/blood-2019-131451
Published: 2019
Journal Articles

Panobinostat (LBH589) in Combination with the β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both in Vitro and In Vivo

Ioanna Savvidou, MD, Tiffany Khong, BSc, PhD, Sophie Whish, Tara Sepehrizadeh, Sridurga Mithraprabhu, PhD MSc, Michael DeVeer, BSc, PhD, Andrew Spencer, DM
Journal: Blood
Blood (2019) 134 (Supplement_1): 5540.
https://doi.org/10.1182/blood-2019-126468
Published: 2019
Journal Articles

Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models

CHI-HENG WU, PhD, Chen-Yen Yang, PhD, Linlin Wang, MD PhD, Hua-Xin Gao, PhD, Rakhshandehroo Taha, Shervin Afghani, Laura Pincus, MD, Ronald Balassanian, MD, James Rubenstein, Ryan Gill, MD PhD, Sourav Bandyopadhyay, PhD, Frank McCormick, PhD, Mark Moasser, MD, Weiyun Z. Ai, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1578.
https://doi.org/10.1182/blood-2019-122589
Published: 2019
Journal Articles

MCL-1 Inhibitor-Induced Killing of Multiple Myeloma Is Modulated By the Relative Level of Expression of Pro-Survival Members of the BCL-2 Family and the Proto-Oncogene MYC

Andrew Spencer, DM, Tiffany Khong, BSc, PhD, Maoshan Chenn, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1825.
https://doi.org/10.1182/blood-2019-127843
Published: 2019
Journal Articles

Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients

Jingjing Shang, Weiqin Yao, Lingzhi Yan, Xiaolan Shi, Ruju Wang, Shuang Yan, Yong Liu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1855.
https://doi.org/10.1182/blood-2019-129434
Published: 2019